Kewaunee Scientific (KEQU)
(Delayed Data from NSDQ)
$34.90 USD
-1.05 (-2.92%)
Updated Apr 26, 2024 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Kewaunee Scientific Corporation falls in the month of April.
All items in Millions except Per Share data.
4/30/2023 | 4/30/2022 | 4/30/2021 | 4/30/2020 | 4/30/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 14 | 7 | 6 | 5 | 11 |
Receivables | 46 | 41 | 35 | 28 | 33 |
Notes Receivable | 0 | 13 | 0 | 0 | 0 |
Inventories | 22 | 24 | 17 | 15 | 17 |
Other Current Assets | 6 | 6 | 3 | 6 | 4 |
Total Current Assets | 88 | 92 | 60 | 54 | 65 |
Net Property & Equipment | 16 | 15 | 16 | 16 | 16 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 2 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 5 | 5 | 4 | 4 | 4 |
Total Assets | 119 | 119 | 89 | 84 | 87 |
Liabilities & Shareholders Equity | 4/30/2023 | 4/30/2022 | 4/30/2021 | 4/30/2020 | 4/30/2019 |
---|---|---|---|---|---|
Notes Payable | 4 | 2 | 7 | 5 | 10 |
Accounts Payable | 24 | 27 | 17 | 13 | 15 |
Current Portion Long-Term Debt | 1 | 1 | 0 | 0 | 1 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 6 | 8 | 6 | 5 | 5 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 4 | 4 | 3 | 3 | 2 |
Total Current Liabilities | 40 | 42 | 34 | 27 | 33 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 1 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 28 | 29 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 4 | 5 | 5 | 10 | 7 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 80 | 83 | 48 | 45 | 40 |
Shareholders Equity | 4/30/2023 | 4/30/2022 | 4/30/2021 | 4/30/2020 | 4/30/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 7 | 7 | 7 | 7 | 7 |
Capital Surplus | 5 | 4 | 4 | 3 | 3 |
Retained Earnings | 29 | 28 | 34 | 38 | 44 |
Other Equity | -2 | -3 | -3 | -9 | -6 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 38 | 36 | 41 | 39 | 48 |
Total Liabilities & Shareholder's Equity | 119 | 119 | 89 | 84 | 87 |
Total Common Equity | 38 | 36 | 41 | 39 | 48 |
Shares Outstanding | 2.80 | 2.70 | 2.70 | 2.70 | 2.70 |
Book Value Per Share | 13.75 | 13.40 | 15.37 | 14.33 | 17.67 |
Fiscal Year End for Kewaunee Scientific Corporation falls in the month of April.
All items in Millions except Per Share data.
1/31/2024 | 10/31/2023 | 7/31/2023 | 4/30/2023 | 1/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 27 | 22 | 22 | 14 | 18 |
Receivables | 41 | 43 | 42 | 46 | 44 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 22 | 22 | 22 | 22 | 21 |
Other Current Assets | 6 | 5 | 7 | 6 | 8 |
Total Current Assets | 96 | 91 | 94 | 88 | 92 |
Net Property & Equipment | 17 | 18 | 17 | 16 | 15 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 5 | 5 | 5 | 5 | 6 |
Total Assets | 126 | 122 | 125 | 119 | 122 |
Liabilities & Shareholders Equity | 1/31/2024 | 10/31/2023 | 7/31/2023 | 4/30/2023 | 1/31/2023 |
---|---|---|---|---|---|
Notes Payable | 3 | 6 | 5 | 4 | 6 |
Accounts Payable | 19 | 19 | 22 | 24 | 25 |
Current Portion Long-Term Debt | 1 | 1 | 1 | 1 | 1 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 7 | 6 | 7 | 6 | 6 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 10 | 5 | 7 | 4 | 5 |
Total Current Liabilities | 42 | 39 | 44 | 40 | 44 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 1 | 1 | 1 | 1 | 1 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 28 | 28 | 28 | 28 | 28 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 4 | 4 | 4 | 5 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 81 | 78 | 84 | 80 | 85 |
Shareholders Equity | 1/31/2024 | 10/31/2023 | 7/31/2023 | 4/30/2023 | 1/31/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 7 | 7 | 7 | 7 | 7 |
Capital Surplus | 5 | 5 | 5 | 5 | 5 |
Retained Earnings | 36 | 34 | 31 | 29 | 28 |
Other Equity | -3 | -3 | -2 | -2 | -3 |
Treasury Stock | 1 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 45 | 43 | 41 | 38 | 36 |
Total Liabilities & Shareholder's Equity | 126 | 122 | 125 | 119 | 122 |
Total Common Equity | 45 | 43 | 41 | 38 | 36 |
Shares Outstanding | 2.90 | 2.90 | 2.90 | 2.80 | 2.80 |
Book Value Per Share | 15.63 | 14.97 | 13.98 | 13.75 | 12.98 |